The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer

despite evidence from randomized trials supporting its use during the study period. Though receipt of such therapy was higher in younger patients and in those at highest risk for recurrence, overall rates of utilization are low. Until data from ongoing randomized trials comparing the outcomes of adjuvant radiation therapy to early salvage therapy become available, our study suggests additional effort is needed to ensure patients receive appropriate care as supported by national practice guidelines and level I evidence. Author Disclosure: H. Sineshaw: None. P.J. Gray: None. J.A. Efstathiou: None. A. Jemal: None.